
Analysts Viewpoint
Goldman analysts initates a Buy rating for Rhythm Pharmaceuticals Inc (RYTM)
In a filing, Rhythm Pharmaceuticals Inc revealed its Chief Financial Officer Smith Hunter C unloaded Company’s shares for reported $3.39
In a filing, Rhythm Pharmaceuticals Inc revealed its Chief Financial Officer Smith Hunter C unloaded Company’s shares for reported $3.39
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
Rhythm Pharmaceuticals Inc’s filing revealed that its Chief Scientific Officer Garfield Alastair unloaded Company’s shares for reported $85483.0 on Jul
Rhythm Pharmaceuticals Inc’s recent filing unveils that its Corporate Controller & CAO German Christopher Paul unloaded Company’s shares for reported